Processing...
Clinical Trials for Pancreas Cancer
Search
Search
There are 214 active trials for advanced/metastatic pancreas cancer.
Click on a trial to see more information.
214 trials meet filter criteria.
Sort by:
HealthScout AI summary: This trial enrolls adults with advanced solid tumors or pancreatic ductal adenocarcinoma harboring a KRAS G12D mutation who have received prior standard therapies, testing ARV-806, an investigational IV protein degrader specifically targeting mutant KRAS G12D. Patients with prior KRAS G12D/pan-KRAS inhibitor exposure or uncontrolled comorbidities are excluded.
ClinicalTrials.gov ID: NCT07023731
HealthScout AI summary: This trial enrolls patients with advanced or metastatic NSCLC, HNSCC, melanoma, or PDAC to receive PF-08046037, an immune-stimulating antibody-drug conjugate targeting PD-L1 and delivering a TLR7 agonist, either as monotherapy or in combination with sasanlimab (anti-PD-1). Participants must have measurable disease and available tumor tissue, with other eligibility based on prior therapies and comorbidities.
ClinicalTrials.gov ID: NCT06974734
HealthScout AI summary: Adults with advanced or metastatic solid tumors harboring homozygous MTAP deletions who have progressed on standard therapy are eligible for treatment with TNG462, a selective PRMT5 inhibitor targeting MTAP-deleted tumor cells, either as monotherapy or in combination with pembrolizumab.
ClinicalTrials.gov ID: NCT05732831
HealthScout AI summary: This trial enrolls adults with select locally advanced or metastatic solid tumors—including hepatocellular, pancreatic, biliary tract, esophageal, breast, head and neck, and certain gynecologic cancers—who have measurable disease and adequate organ function. Patients receive intravenous ABBV-400, an antibody-drug conjugate targeting c-Met and delivering a topoisomerase 1 inhibitor, as monotherapy.
ClinicalTrials.gov ID: NCT06084481
HealthScout AI summary: Eligible adult patients with advanced, relapsed, or treatment-refractory solid tumors—including specific expansion cohorts for breast, pancreatic, ovarian, or colorectal cancer—may receive SON-DP, a first-in-class investigational protein that reprograms malignant cells into normal tissue cells rather than killing them, via IV infusion.
ClinicalTrials.gov ID: NCT05989724
HealthScout AI summary: This trial enrolls adults with advanced solid tumors (any histology) who have progressed on or are unsuitable for standard therapies and have measurable disease, regardless of tumor FRα or TRPV6 status. Patients receive IV CBP-1019, a bi-ligand-drug conjugate that targets Folate Receptor alpha and TRPV6 to deliver a topoisomerase I inhibitor directly to tumor cells.
ClinicalTrials.gov ID: NCT05830097
HealthScout AI summary: This trial enrolls adults with unresectable or metastatic, mismatch repair-proficient colorectal cancer or pancreatic ductal adenocarcinoma harboring vaccine-covered KRAS mutations who have progressed after first-line chemotherapy, and treats them with a mutant KRAS-targeted peptide vaccine plus balstilimab (anti-PD-1) and botensilimab (Fc-enhanced anti-CTLA-4). Immunotherapy-naive patients with measurable disease and good performance status are eligible.
ClinicalTrials.gov ID: NCT06411691
HealthScout AI summary: This trial enrolls adults with metastatic or unresectable, RAS-mutant colorectal or pancreatic cancer (including KRAS G12D subsets), and tests oral RAS(ON) inhibitors—RMC-6236 (a multi-selective tri-complex RAS inhibitor) and RMC-9805 (a KRAS G12D-selective molecular glue)—either as monotherapy or combined with standard therapies such as mFOLFOX6, mFOLFIRINOX, gemcitabine/nab-paclitaxel, bevacizumab, or cetuximab. All patients must have ECOG 0-1 and adequate organ function.
ClinicalTrials.gov ID: NCT06445062
HealthScout AI summary: Adults with unresectable/metastatic GI cancers—previously treated colorectal or pancreatic ductal adenocarcinoma, and biliary tract cancers (treatment‑naive or previously treated)—receive sacituzumab tirumotecan (MK‑2870), a TROP2‑targeted antibody–drug conjugate delivering a belotecan‑derived topoisomerase I inhibitor, as monotherapy or combined with 5‑FU/leucovorin, or with cisplatin plus pembrolizumab. Excludes significant ophthalmologic disease and prior steroid‑requiring ILD/pneumonitis; prior therapy toxicities must have resolved.
ClinicalTrials.gov ID: NCT06428409
HealthScout AI summary: Adults with metastatic CRPC, pancreatic cancer, or HPV-negative SCCHN lacking effective options receive triplet therapy with evofosfamide (hypoxia-activated DNA crosslinking prodrug) plus zalifrelimab (anti–CTLA-4) and balstilimab (anti–PD-1). Open-label dose-escalation followed by disease-specific expansions; key exclusions include significant prior immune toxicity, active autoimmune disease, QTc ≥470 msec/TdP risk, uncontrolled CNS disease/infections, and use of strong/moderate CYP3A4 modulators or QT-prolonging drugs.
ClinicalTrials.gov ID: NCT06782555